Management of newly diagnosed metastatic hormone‐sensitive prostate cancer: A survey of UK Uro‐oncologists

Aim To explore the practice and views of uro-oncologists in the United Kingdom regarding their use of chemotherapy and androgen receptor-targeted agents (ARTAs) in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Methods An expert-devised paper or online questionnaire was completed by members of the British Uro-oncology Group. Results All respondents stated that they would offer patients with newly diagnosed...